EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Antipsychotic Induced Symptomatic Hyperprolactinemia: Are Dopamine Agonists Safe?

Unax Lertxundi, Saioa Domingo-Echaburu, Javier Peral, Montserrat García

Psychopharmacology Bulletin · 12.08.2025 · 44 (3) · 66-68

DOI: 10.64719/pb.4078 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Psychopharmacology Bulletin, online erschienen am 12.08.2025. Verfasst von Unax Lertxundi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Lertxundi, Pharmacy Service, Red de Salud Mental de Araba, C/alava 43, Vitoria-Gasteiz, Araba, Spain. Dr. Domingo-Echaburu, Pharmacy Service, Hos…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Published literature shows that dopamine agonists can reverse antipsychotic-induced hyperprolactinemia without worsening psychotic symptoms in the majority of schizophrenic patients. However, psychiatrists have been reluctant to use drugs with dopaminergic properties for fear of exacerbating psychiatric symptoms. There are reported cases of psychosis worsening published for both cabergoline and bromocriptine. Cabergoline has proven to be more effective and safe when used to treat hyperprolactinemia, but whether cabergoline is also safer than bromocriptine in antipsychotic induced hyperprolactinemia remains unproven.

Schlagwörter

Stichwörter der Autor:innen

AntipsychoticBromocriptineCabergolineHyperprolactinemiaPharmacovigilance

Autor:innen und Institutionen

  • Dr. Lertxundi, Pharmacy Service, Red de Salud Mental de Araba, C/alava 43, Vitoria-Gasteiz, Araba, Spain. Dr. Domingo-Echaburu, Pharmacy Service, Hospital Alto Deba, Avda, Nafarroa, 16, Arrasate Gipuzkoa, Spain. Dr. Per…

Zitieren

APA

Lertxundi, U., Domingo-Echaburu, S., Peral, J., & García, M. (2025). Antipsychotic Induced Symptomatic Hyperprolactinemia: Are Dopamine Agonists Safe?. Psychopharmacology Bulletin, 44(3), 66-68. https://doi.org/10.64719/pb.4078

Vancouver

Lertxundi U, Domingo-Echaburu S, Peral J, García M. Antipsychotic Induced Symptomatic Hyperprolactinemia: Are Dopamine Agonists Safe?. Psychopharmacology Bulletin. 2025;44(3):66-68. doi:10.64719/pb.4078

BibTeX
@article{Lertxundi2025,
  author = {Lertxundi, Unax and Domingo-Echaburu, Saioa and Peral, Javier and García, Montserrat},
  title = {Antipsychotic Induced Symptomatic Hyperprolactinemia: Are Dopamine Agonists Safe?},
  journal = {Psychopharmacology Bulletin},
  year = {2025},
  volume = {44},
  number = {3},
  pages = {66--68},
  doi = {10.64719/pb.4078}
}
Kostenlos starten →